| KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ... New England Journal of Medicine 383 (13), 1207-1217, 2020 | 1280 | 2020 |
| Sotorasib for Lung Cancers with KRAS p.G12C Mutation F Skoulidis, BT Li, GK Dy, TJ Price, GS Falchook, J Wolf, A Italiano, ... New England Journal of Medicine 384 (25), 2371-2381, 2021 | 1063 | 2021 |
| Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer HL Kindler, G Friberg, DA Singh, G Locker, S Nattam, M Kozloff, DA Taber, ... J Clin Oncol 23 (31), 8033-8040, 2005 | 621 | 2005 |
| Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 AW Tolcher, J Sarantopoulos, A Patnaik, K Papadopoulos, CC Lin, ... Journal of Clinical Oncology 27 (34), 5800-5807, 2009 | 414 | 2009 |
| Phase II study of Ganitumab, a fully human anti–type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round … WD Tap, G Demetri, P Barnette, J Desai, P Kavan, R Tozer, PW Benedetto, ... Journal of Clinical Oncology 30 (15), 1849-1856, 2012 | 233 | 2012 |
| Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and … HS Nimeiri, AM Oza, RJ Morgan, G Friberg, K Kasza, L Faoro, R Salgia, ... Gynecologic oncology 110 (1), 49-55, 2008 | 192 | 2008 |
| A first-in-human study of conatumumab in adult patients with advanced solid tumors RS Herbst, R Kurzrock, DS Hong, M Valdivieso, CP Hsu, L Goyal, G Juan, ... Clinical cancer research 16 (23), 5883-5891, 2010 | 154 | 2010 |
| Chemotherapy in endometrial cancer. JC Obel, G Friberg, GF Fleming Clinical advances in hematology & oncology: H&O 4 (6), 459-468, 2006 | 84 | 2006 |
| Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors I Aldoss, RC Bargou, D Nagorsen, GR Friberg, PA Baeuerle, SJ Forman Leukemia 31 (4), 777-787, 2017 | 72 | 2017 |
| Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): updated results of a multi-center phase II trial HL Kindler, G Friberg, WM Stadler, DA Singh, G Locker, S Nattam, ... Journal of Clinical Oncology 22 (14_suppl), 4009-4009, 2004 | 66 | 2004 |
| Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors T Doi, H Murakami, A Ohtsu, N Fuse, T Yoshino, N Yamamoto, N Boku, ... Cancer Chemotherapy and Pharmacology 68, 733-741, 2011 | 64 | 2011 |
| AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models TL Bush, M Payton, S Heller, G Chung, K Hanestad, JB Rottman, ... Molecular cancer therapeutics 12 (11), 2356-2366, 2013 | 51 | 2013 |
| Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer HL Kindler, G Friberg, L Skoog, K Wade-Oliver, EE Vokes American journal of clinical oncology 28 (4), 340-344, 2005 | 44 | 2005 |
| Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G) G Friberg, K Kasza, EE Vokes, HL Kindler Journal of Clinical Oncology 23 (16_suppl), 3020-3020, 2005 | 41 | 2005 |
| A clinical study of competency to consent to treatment in pediatrics. SB Billick, W Burgert 3rd, G Friberg, AV Downer, SM Bruni-Solhkhah The journal of the American Academy of Psychiatry and the Law 29 (3), 298-302, 2001 | 40 | 2001 |
| First-in-human study of AMG 319, a highly selective, small molecule inhibitor of PI3Kδ, in adult patients with relapsed or refractory lymphoid malignancies MC Lanasa, M Glenn, AR Mato, SD Allgood, S Wong, B Amore, G Means, ... Blood 122 (21), 678, 2013 | 39 | 2013 |
| Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs S Eschweiler, C Ramírez-Suástegui, Y Li, E King, L Chudley, J Thomas, ... Nature 605 (7911), 741-746, 2022 | 37 | 2022 |
| A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G) J Sarantopoulos, AC Mita, M Mulay, O Romero, J Lu, F Capilla, L Chen, ... Journal of Clinical Oncology 26 (15_suppl), 3583-3583, 2008 | 37 | 2008 |
| A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors M Carducci, M Shaheen, B Markman, S Hurvitz, D Mahadevan, D Kotasek, ... Investigational new drugs 36, 1060-1071, 2018 | 35 | 2018 |
| Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors LS Rosen, I Puzanov, G Friberg, E Chan, YC Hwang, H Deng, J Gilbert, ... Clinical Cancer Research 18 (12), 3414-3427, 2012 | 35 | 2012 |
Igor PuzanovRoswell Park Cancer InstituteDirección de correo verificada de roswellpark.org
